We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Noninvasive Test Developed for Colorectal Cancer

By LabMedica International staff writers
Posted on 31 Oct 2012
Print article
A novel noninvasive test for colorectal cancer (CRC) screening demonstrated high sensitivity for detecting colorectal malignancy.

The test measures different kinds of DNA changes, known as methylation and mutation, along with a measure of fecal blood and by combining these measures, doctors can be shown the kinds of biological changes that are most frequently found in precancers and cancers in the colon.

Scientists at the Exact Sciences Corporation (Madison, WI, USA) working with those at the Mayo Clinic, (Rochester, MN, USA) analyzed 1,003 patient samples from 36 study sites. They developed an analytic algorithm for the novel, automated stool DNA-based test platform, which generated a positive or negative result for each patient. The specimens were collected either before colonoscopy bowel preparation in screening and surveillance patients or at least seven days postcolonoscopy from patients with colorectal cancer and large precancerous growths.

The control group included 796 patients with negative colonoscopies or small polyps of less than 1 cm, and the case group included 207 patients with confirmed CRC or precancers. The team was able to demonstrate that CRC and advanced precancers can be detected noninvasively by a manual multitarget stool DNA-based test (sDNA-MT) comprising exfoliated DNA markers plus β-actin and fecal hemoglobin. The clinical performance of the sDNA-MT test, using an optimized automated analytic platform and logistic algorithm could facilitate the routine performance of sDNA-MT for CRC screening by molecular diagnostics capable clinical laboratories.

Automated methylation, mutation and actin assays were performed with a Hamilton STARlet fluid handler (Hamilton Robotics; Reno, NV, USA), and Quantitative Allele-specific Real-time Target and Signal amplification (QuARTS) run on an ABI 7500 FastDx real time thermal cycler (Applied Biosystems; Foster City, CA, USA). The test detected 98% of all cancers as well as 83% of precursors with high-grade dysplasia, and 57% of precursors 1 cm or larger overall, at 90% nominal specificity. CRC patients were typically referred to colonoscopy for symptoms and test sensitivity may be elevated relative to that seen with screening.

Graham P. Lidgard, PhD, the chief science officer at Exact Sciences, said, "We are encouraged by the results of this study for detecting cancer and cancer precursors, especially the precursor lesions with high-grade dysplasia, an abnormality broadly recognized as being associated with a higher risk for progression to cancer itself. Current screening tests using only fecal occult blood are biologically limited in their ability to detect precursors to colorectal cancer." The study was presented at the 11th Annual American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, held October 16-19, 2012, in Anaheim (CA, USA).

Related Links:

Exact Sciences Corporation
Mayo Clinic
Hamilton Robotics


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.